|
 |
| home > ebr > Autumn 2005 |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In the Editor's Letter, Dr Helen Tayton-Martin introduces the articles in this issue |
|
|
|
|
| G Steven Burrill, CEO of Burrill & Company, considers the latest deal-making trends, in The Pendulum Swings towards M&As and Partnering for Biotechs |
|
|
| In Accessing Innovation: The Role of Equity Investments in Pharmaceutical R&D and Licensing Agreements, Andrea Elliot-Smith, Business Analyst at Pharmaventures, examines an important component of pharma-biotech collaborations |
|
|
| Universities are situated at the crossroads of research, education and innovation, but is their potential limited by poor links between academia and industry? Ben Rapinoja, Attorney-at-Law and Aura Soininen, LLM at Borenius & Kemppinen Ltd, discuss the possibilities, in University-Industry Collaboration and Technology Transfer |
|
|
| Olivia Lindau-Jonsson, Project Co-ordinator at Business Region Göteborg, suggests that consolidation might be the only way for biotech companies to gain access to financing, strengthen liquidity and survive in a global environment, in Can University Initiatives Influence the M&A Trend in the Biotech Industry? |
|
|
|
|
| The realisation of large-scale proteomics for drug discovery and proteome mapping will require a solution for the full automation of the bioinformatics pipeline, assert Andrew Dowsey and Guang-Zhong Yang at the Royal Society/Wolfson MIC Laboratory, Imperial College London, in The Road to High-Throughput Proteomics |
|
|
| In Pharmacogenomics in Medical R&D - Catching up with Great Expectations, Dr Duncan McHale, European Head of Clinical Pharmacogenomics at Pfizer Global Research and Development, argues that, while initial hopes have been tempered, optimism remains |
|
|
| Professor Dr Hans-Georg Frank, CSO and Dr Udo Haberl, Head of Drug Design at AplaGen GmbH, predict future improvements on an established therapy, in Treatment of Anaemia - Erythropoietins and Beyond |
|
|
| Delivery by needle may one day be a practice of the past, according to Dr Rocky Cranenburgh, Molecular Genetics Team Leader at Cobra. Discover why in Advances in Recombinant Vaccine Delivery: Live Bacterial Vectors |
|
|
|
|
| Will the amalgamation of individually limited approaches create a new holistic model? Pieter Muntendam, Managing Director and President at BG Medicine believes so, in Integrating Approaches to Biomarker Development - Transcriptomic, Proteomic, Metabolomic - in Drug Discovery |
|
|
| In Nature's Catalysts and their Applications in the Pharmaceutical Industry, Jenny Littlechild, Professor of Biological Chemistry and Director of the Biocatalysis Centre at the University of Exeter, explores the utility of enzymes found in micro-organisms and seaweeds |
|
|
| Willi Hunziker, CEO of Frimorfo, investigates strategies to reduce difficulties in target selection, in Drowning in Numbers or Hitting Targets? Gene Pool Validation for Refined Drug Development |
|
|
| Paul Lang, Head of the Cellular Pharmacology Group, Dominique Besson, Head of HTS, and Alexander Scheer, Head of the Molecular Screening and Cellular Pharmacology Department at the Serono Pharmaceutical Research Institute, examine approaches to HTS, in Evolution not Revolution - Adopting the High-Throughput Screening Philosophy |
|
|
|
|
| Further commitment is needed to tackle 'neglected' diseases in developing countries, assert Dr Gerald Dunstan, Principal, and Dr Caroline Wright, Research Analyst, Healthcare & Life Sciences Consulting Practice at Cambridge Consultants, in Development of Biological Therapies for Orphan Indications |
|
|
| Dr Yvonne Perrie, Lecturer in Pharmaceutics/Drug Delivery at Aston Pharmacy School, Aston University, Birmingham, UK, assesses the advantages of Liposome Delivery of Sparingly Soluble Drugs |
|
|
| Regional and international networks increase co-operation and enhance research and development, contends Dr Kate Rowley, Knowledge Transfer Officer at the Scottish Association for Marine Science, Dunstaffnage Marine Laboratory, in Casting Nets to Catch Solutions - New Initiatives in Marine Biotechnology |
|
|
| Dr Paul Lloyd-Evans, Development Scientist for Clinical Biotechnology Centre and Keith Williams, Operations Manager at the Clinical Biotechnology Centre, highlight issues associated with the development of orphan therapies, in Bench to Bedside - A Case Study of the Technology Transfer of a Biopharmaceutical from the Research Laboratory into GMP for Clinical Trials |
|
|
|
|
| A guide to successful navigation of the intellectual property path is provided in Biomanufacturing: Patent Issues and IP Strategy throughout the Product Life Cycle, by Lorna Brazell, Partner at Bird & Bird |
|
|
| In Search of a Flexible Formatted Tool: Should Disposables be the Golden Rule? Edwin H Schwander, Field Business Development Manager at Nunc A/S, reasons on the unexploited potential of disposables for mass production |
|
|
| Michel HM Eppink, Director DSP Methodology and Troubleshooting, Diosynth Biotechnology Europe, probes Platform Technology for Developing Purification Processes |
|
|
| Dr Maren Topf-Schleuning, Head of Business Development at berlinbiotechpark, asks whether the current equilibrium between supply and demand is set to vanish, in Biomanufacturing Capacity - Bottleneck for the Evolving Biotechnology Industry? |
|
|
|
| In Search of Deal Data: Taking a Look at PartneringreviewTM - Annual Review 2004 - Dr Helen Tayton-Martin, Corporate Development Officer, Allevia AG and Advisory Editor, European Biopharmaceutical Review, sizes up the statistics |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
GEMÜ goes to Russia
Moscow, 27th May 2008.
At the opening ceremony the founder of the company and
managing partner, Fritz Müller, gave the starting signal for the new sales and
marketing subsidiary OOO GEMÜ Russia which will be managed by Mr Hans-Joachim
Götze. The guests present at the ceremony included the executive board of the
GEMÜ Group and Russian customers. GEMÜ Russia is the 16th sales and
marketing subsidiary in the GEMÜ Group.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
